Clinical trials: Other Endocrine/Nutritional/Metabolic Disorder
- Condition Other Endocrine/Nutritional/Metabolic Disorder
- Funder type Industry (pharma, biotech, devices)
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate…
- Trial name
- SOTA-INS (NCT03285594)
- Testing
- Sotagliflozin, Insulin glargine (HOE901), Oral Antidiabetes Drugs (OADs)
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 571 people
- Sponsor
- Lexicon Pharmaceuticals